간암 진단 시장 규모, 점유율 및 성장 분석 : 검사 유형별, 암 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Liver Cancer Diagnostics Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.67 Billion in 2025 to USD 3.52 Billion by 2033, growing at a CAGR of 9.82% during the forecast period (2026-2033).

The global liver cancer diagnostics market is experiencing significant growth driven by the high prevalence of liver cancer and chronic liver ailments, coupled with an increasing focus on early detection through advanced screening initiatives. Innovations in molecular diagnostics and imaging technologies, along with a rise in liquid biopsy solutions, are enhancing diagnostic accuracy and patient management. Key investments in circulating tumor DNA and AI-based radiology platforms further bolster this market. Additionally, the emphasis on preventive oncology, combined with a rising need for effective surveillance of conditions like hepatocellular carcinoma and chronic hepatitis infections, contributes to expanding market opportunities. Nevertheless, challenges such as high costs, accessibility issues, and regulatory hurdles may hinder broader market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cancer Diagnostics Market Segments Analysis

Global liver cancer diagnostics market is segmented by test type, cancer type, end-user,and region. Based on test type, the market is segmented into Liver Function Tests (LFTs), Tumor Marker Tests (AFP), Imaging (CT, MRI, Ultrasound), biopsy, and liquid biopsy. Based on cancer type, the market is segmented into Hepatocellular Carcinoma (HCC),Cholangiocarcinoma,and metastatic liver cancer. Based on end-user, the market is segmented into hospitals, diagnostic labs,and cancer centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America,and the Middle East & Africa.

Driver of the Global Liver Cancer Diagnostics Market

One of the key market drivers for the Global Liver Cancer Diagnostics Market is the rising prevalence of liver cancer, largely attributed to increasing rates of hepatitis infections, heavy alcohol consumption, and the rising incidence of obesity and associated metabolic syndromes. As awareness regarding liver disease expands, there is a growing demand for early and accurate diagnostic procedures. Advanced imaging technologies, along with biomarker identification and molecular diagnostics, are enhancing diagnostic accuracy, leading healthcare providers to adopt these innovative solutions more readily. This shift is crucial for effective treatment planning and improving patient outcomes, thereby driving market growth significantly.

Restraints in the Global Liver Cancer Diagnostics Market

One key market restraint for the global liver cancer diagnostics market is the high cost of diagnostic procedures and advanced imaging technologies. The financial burden associated with these diagnostic methods can limit accessibility for many patients, particularly in low- and middle-income regions. Additionally, the lack of awareness and understanding of liver cancer symptoms among the general population can lead to delayed diagnoses, further complicating treatment and care. These factors collectively hinder the expansion of the market, as healthcare providers may be reluctant to invest in costly diagnostic tools, thus impacting overall patient outcomes and survival rates in liver cancer cases.

Market Trends of the Global Liver Cancer Diagnostics Market

The Global Liver Cancer Diagnostics market is witnessing a significant shift towards the adoption of liquid biopsy techniques, driven by a growing demand for minimally invasive diagnostic options. These advancements promise earlier detection and more effective disease monitoring, enhancing patient outcomes. Collaborative efforts among diagnostic firms, healthcare providers, and insurance companies are paving the way for integrating liquid biopsies alongside traditional imaging and biopsy methods, thereby optimizing diagnostic accuracy. This trend focuses on refining assays and standardizing pre-analytical processes to streamline clinical integration, ultimately reducing patient discomfort and empowering healthcare professionals in making informed clinical decisions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Liver Cancer Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Liver Function Tests (LFTs)
• Tumor Marker Tests (AFP)
• Imaging (CT)
• MRI
• Ultrasound
• Biopsy
• Liquid Biopsy

Global Liver Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Hepatocellular Carcinoma (HCC)
• Cholangiocarcinoma
• Metastatic Liver Cancer

Global Liver Cancer Diagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Labs
• Cancer Centers

Global Liver Cancer Diagnostics Market Size by Region & CAGR (2026-2033)

• Market Overview
• Asia-Pacific
• North America
• Europe

Global Liver Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Cancer Type, End-User, Region)
  • US
  • Canada
• Europe (Test Type, Cancer Type, End-User, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Cancer Type, End-User, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Cancer Type, End-User, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Cancer Type, End-User, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grail Inc. (Illumina)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Burning Rock Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus Labs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EarlySense
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trovagene Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynvenio Biosystems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations